Invicta Diagnostic IPO Subscription StatusĀ
Invicta Diagnostic IPO subscribed over 0.54x on its first day till 5.00 PM on December 1st, 2025.Ā
- The Invicta Diagnostic IPO subscription QIB investors’ portion is 1.00 times, while NII subscribed 0.68 times, and RII investors subscribed 0.29 times.Ā
- The company has received bids for 12,62,400 shares against 23,44,000 shares on offer on the first day of subscription.Ā
- Invicta Diagnostic’s IPO was subscribed over 0.54x on its day 1.Ā
About Invicta Diagnostic CompanyĀ
Invicta Diagnostic Limited has been engaged in providing radiology and pathology solutions since January 2021. Under the brand āPC Diagnosticsā, the company provides pathology and radiology tests, including imaging and teleradiology. Invicta runs 7 diagnostic centres and a central lab across Mumbai, Maharashtra. As of October 31, 2025, the company provides a wide range of medical specialty tests, including 60 routine and 487 specialized pathology tests, along with 96 basic and 130 advanced radiology tests.
The company offers a wide range of pathology and radiology tests, such as biochemistry and clinical pathology, cytogenetics, and high-end molecular diagnostics, basic echocardiograms, X-rays, ultrasounds, CT scans, MRI scans, and PET CT scans. Moreover, the company also runs a hub-and-spoke model in the Mumbai Metropolitan Region with a main hub in Thane West, 3 additional hubs in Bhayandar, Byculla, and Marol, and 3 spokes in Lower Parel, Sewri, and Kalwa.
Invicta Diagnostic IPO GMPĀ
Invicta Diagnostic IPO GMP was ā¹0 as of Monday, 1st December 2025. That indicates the IPO is trading at ā¹85 with a ā¹0 premium in the grey market against the issue price of ā¹85.Ā
